Care Step Pathway – Neuropathy (motor or sensory nerve impairment or damage)

**Assessment**

**Look:**
- Does the patient appear weak?
- Does the patient appear uncomfortable?
- Altered ambulation or general movement?
- If muscular weakness is present, any respiratory difficulties apparent?
- Abnormal gait, paralysis, or fine motor changes?

**Listen:**
- Does the patient report weakness (unilateral or bilateral)?
- Has the patient reported falls or tripping?
- Does the patient report new or worsened pain, numbness, burning, or tingling?
- Does the patient report difficulty walking or holding items?
- Are symptom(s) intermittent or constant?

**Recognize:**
- Motor deficits
- Sensory deficits
- Mental status changes
- Paresthesias
- Laboratory values
- Past history of toxicities with other therapies
- Does the patient have diabetes mellitus?
- Are there neurologic signs and symptoms?
- Results of prior imaging
  - Metastases to spinal cord
  - Other metastases that may cause symptoms

**Grading Toxicity: ULN**

<table>
<thead>
<tr>
<th>Grade 1 (Mild)</th>
<th>Grade 2 (Moderate)</th>
<th>Grade 3 (Severe)</th>
<th>Grade 4 (Potentially Life-Threatening)</th>
<th>Grade 5 (Death)</th>
</tr>
</thead>
</table>
| Peripheral Motor: 
  - Asymptomatic; clinical or diagnostic observations only 
  - No intervention indicated |
| Peripheral Motor: 
  - Moderate symptoms; limiting instrumental ADLs |
| Peripheral Motor: 
  - Severe symptoms; limiting self-care ADLs; requires assistive devices |
| Peripheral Motor: 
  - Life-threatening; urgent intervention indicated |
| Peripheral Motor: 
  - Death |

**Peripheral Sensory:**
- Asymptomatic; loss of deep tendon reflexes or paresthesia
- Asymptomatic; clinical or instrumental ADLs
- Severe symptoms; limiting self-care ADLs

**Management**

**Overall Strategy:**
- Screen for neuropathy causes: diabetes with HbA1C, vit B12, folates, TSH, and HIV
- Rule out infectious, noninfectious, disease-related etiologies (medications, metabolic/endocrine disorders, environmental exposures, vascular or autoimmune, trauma)
- High-dose steroids* (0.5–1 mg/kg/day prednisone or equivalent) to be used
- Ipilimumab to be withheld for Grade 2 event, nivolumab for first occurrence of Grade 3 event, and pembrolizumab based on disease severity; ipilimumab to be discontinued for Grade 2 events persisting ≥6 weeks or inability to reduce steroid* dosage to ≤7.5 mg prednisone or equivalent per day; pembrolizumab or nivolumab to be discontinued for Grade 3/4 events that recur, persist ≥12 weeks, or inability to reduce steroid dosage to ≤10 mg prednisone or equivalent per day
- Guillain–Barré syndrome to be managed in the ICU setting, with particular attention to protection of the airway
- Neurology consult
  - Consideration of electromyelography and nerve conduction tests
  - Immune globulin infusions
  - Plasmapheresis
- Taper steroids* slowly over at least 4 weeks once symptoms improve
- If needed, obtain physical therapy or occupational therapy consult (for both functional assessment and evaluate safety of patient at home)
- Supportive medications for symptom management (e.g., gabapentin, pregabalin, or duloxetine)
- As needed, address environmental modifications and safety: fall prevention, thermal injury, etc.
- Encourage appropriate exercise to maintain mobility/functionality

**Implementation:**
- Compare baseline assessment; grade & document neuropathy and etiology (diabetic, medication, vascular, chemotherapy)
- Early identification and evaluation of patient symptoms
- Early intervention with lab work and office visit if neuropathy symptoms suspected

**"Administering Corticosteroids:"
Steroid taper instructions/calendar as a guide but not an absolute
- Taper should consider patient’s current symptom profile
- Close follow-up in person or by phone, based on individual need & symptomatology
- Steroids cause indigestion; provide antacid therapy daily as gastric ulcer prevention while on steroids (e.g., proton pump inhibitor or H2 blocker if prednisone dosage is >20 mg/day)
- Review steroid medication side effects: mood changes (angry, reactive, hyperaware, euphoric, manic), increased appetite, interrupted sleep, oral thrush, fluid retention
- Be alert to recurring symptoms as steroids taper down & report them (taper may need to be adjusted)

**Long-term high-dose steroids:**
- Consider antimicrobial prophylaxis (sulfamethoxazole/trimethoprim double dose MWF; single dose if used daily) or alternative if sulfa-allergic (e.g., atovaquone [Mepron®] 1500 mg po daily)
- Consider additional antiviral and antifungal coverage
- Avoid alcohol/acetaminophen or other hepatotoxins
- If extended steroid use, risk for osteoporosis; initiate calcium and vitamin D supplements

**RED FLAGS:**
- Guillain–Barré syndrome
- Myasthenia gravis
- Pain, numbness, and asymmetrical weakness consistent with a vasculitis syndrome

ADLs = activities of daily living; HIV = human immunodeficiency virus; po = by mouth; TSH = thyroid-stimulating hormone